
Starling
Starling is a YC Winter 2022 (W22) company. Based in Houston, TX, USA. Team of 5.
About Starling
Summary
Starling builds a toilet-mounted mass spectrometry device that continuously analyzes urine at home, replacing periodic lab tests and clinic visits. The platform flags early changes tied to conditions such as recurrent UTIs, benign prostatic hyperplasia, and diabetes, enabling clinicians to intervene before hospitalizations occur. Clinician partners receive remote patient monitoring reimbursements without changing their clinical workflows.
Go-to-market
Clinicians and health systems are the target buyers, acquiring the platform as a remote patient monitoring service billed through existing reimbursement codes.
From the Y Combinator listing
AI enabling digital urine diagnostics in the home
Starling is building a urine diagnostic remote patient monitoring platform that seamlessly integrates into anyone's bathroom routine. By detecting early changes in a patient's urine using our toilet indwelling mass spectroscopy device, our platform is aiming to prevent hospitalizations from numerous conditions like recurrent UTIs, BPH exacerbations, or diabetes. We do this while creating significant new annual revenues for our clinician partners from remote patient monitoring reimbursements without requiring any significant changes in a staff's day to day schedule.
Facts
- Healthcare / Healthcare -> Diagnostics
- Houston, TX, USA
- 5
- Active
- Early
Founders (2)
- Drew Hendricks
- Hannah McKenney
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works